InsiderSignal.AI

InsiderSignal.ai

UTHR - United Therapeutics Corp

Insider Sale by Mahon Paul A (EVP, GC)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Mahon Paul A, serving as EVP, GC at United Therapeutics Corp (UTHR), sold 8,300 shares at $529.95 per share, for a total transaction value of $4,398,611.00. Following this transaction, Mahon Paul A now holds 45,172 shares of UTHR.

This sale represents a 16.00% decrease in Mahon Paul A's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, March 19, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 19, 2026, meaning the disclosure happened on the same day as the trade.

United Therapeutics Corp operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Mahon Paul A

EVP, GC

Paul A. Mahon is an Executive Vice President, General Counsel, and Corporate Secretary at United Therapeutics Corporation (UTHR), a role he has held since 2003.[[2]](https://unither.com/about-us/leadership/paul-a-mahon)[[8]](https://unither.com/about-us/leadership) He has been involved with the company since its inception in 1996, initially serving as General Counsel and Corporate Secretary while acting as principal and managing partner of a law firm specializing in technology and media law; he joined full-time in 2001 as Senior Vice President, General Counsel, and Corporate Secretary.[[2]](https://unither.com/about-us/leadership/paul-a-mahon) Mahon holds a J.D. and continues to oversee legal affairs for United Therapeutics, a biopharmaceutical company focused on pulmonary arterial hypertension treatments.[[2]](https://unither.com/about-us/leadership/paul-a-mahon)[[8]](https://unither.com/about-us/leadership) As of early 2026, he beneficially owns approximately 36,781 shares of UTHR stock following recent option exercises and sales under a Rule 10b5-1 trading plan, with an estimated net worth exceeding $11 million from his holdings.[[1]](https://www.stocktitan.net/sec-filings/UTHR/form-4-united-therapeutics-corp-insider-trading-activity-0e09789572e6.html)[[3]](https://www.gurufocus.com/insider/74259/paul-a-mahon) Over the past five years, he has executed 66 insider transactions, all sells, reflecting routine compensation-related activity.[[3]](https://www.gurufocus.com/insider/74259/paul-a-mahon)

View full insider profile →

Trade Price

$529.95

Quantity

8,300

Total Value

$4,398,611.00

Shares Owned

45,172

Trade Date

Thursday, March 19, 2026

4 days ago

SEC Filing Date

Thursday, March 19, 2026

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About United Therapeutics Corp

Company Overview

No company information available
View news mentioning UTHR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4920763

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime